✦ LIBER ✦

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

✍ Scribed by Michael Pfreundschuh; Lorenz Trümper; Anders Österborg; Ruth Pettengell; Marek Trneny; Kevin Imrie; David Ma; Devinder Gill; Jan Walewski; Pier-Luigi Zinzani; Rolf Stahel; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Tuula Lehtinen; Armando López-Guillermo; Claudia Corrado; Adriana Scheliga; Noel Milpied; Myriam Mendila; Michelle Rashford; Evelyn Kuhnt; Markus Loeffler

Book ID: 117783903
Publisher: The Lancet
Year: 2006
Tongue: English
Weight: 161 KB
Volume: 7
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(06)70664-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CHOP-like chemotherapy with or without r

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

✍ Michael Pfreundschuh; Evelyn Kuhnt; Lorenz Trümper; Anders Österborg; Marek Trne 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 853 KB

Prognostic significance of maximum tumou

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

✍ Michael Pfreundschuh; Anthony D Ho; Eva Cavallin-Stahl; Max Wolf; Ruth Pettengel 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 270 KB